Q1 preflight: **18/18 PASS**. Recon stopped at **Q4: AC-403 needs adjudication**. The [draft plan](/home/moose/nextjs/CYBER_PHARMA/cyber-pharma-dev-v1-phase-3/agent_docs/ACTIONS/RRM-004-CYBER-PHARMA/QAM/QAM_TEST_PLAN.md) is saved and unapproved.

ADMIN and MEMBER each signed in once and logged out successfully. Both protected routes returned 200 with zero console errors; access redirected to `/auth` after logout. The server stopped and temporary browser state was removed. Final Q1 privacy scans found zero leaks; Q5 cleanup remains pending.

The draft proposes:

| Order | Q2 work |
|---|---|
| 1 | Re-pin HEAD and rerun the ordered preflight with Q2’s fresh install. |
| 2 | Independently verify pins, registry/audit results, lockfile changes and native metadata; prove the version validator rejects invalid synthetic input. |
| 3 | Build with blank and placeholder environments; test PNG optimization, remote-host denial with its required body, direct images and cache-header controls. |
| 4 | Run TypeScript, ESLint and full Jest; compare route/test counts, preserved files and engineering artifacts against their stated references. |
| 5 | Make the separate real-target build; run 24 contracted role/route/viewport/theme cells plus four signed-out home controls, using one Q2 sign-in per role. |
| 6 | Return the AC evidence matrix, findings and separate pilot metrics. Run Q5 privacy/cleanup only on its command; retest only after an approved repair. |

Expectations come from the frozen spec/rulings, registry, baseline history, source and QA’s own outputs. The plan includes negative controls, evidence/status rules, credential protections and the bounded retest procedure. Product verification remains **NOT RUN**.

The contradiction is [AC-403’s allowlist](/home/moose/nextjs/CYBER_PHARMA/cyber-pharma-dev-v1-phase-3/agent_docs/ACTIONS/RRM-004-CYBER-PHARMA/ACCEPTANCE_SPEC.md:47): the baseline diff includes RRM-002/RRM-003 closeout records and the campaign journal, while [P0 explicitly authorizes some of those edits](/home/moose/nextjs/CYBER_PHARMA/cyber-pharma-dev-v1-phase-3/agent_docs/ACTIONS/RRM-004-CYBER-PHARMA/CLAUDY_PROMPTS.md:9). No addendum/erratum reconciles the grade. Q1-C01 is **ADJUDICATE**, not a product failure.

[Stop report](/home/moose/nextjs/CYBER_PHARMA/cyber-pharma-dev-v1-phase-3/agent_docs/ACTIONS/RRM-004-CYBER-PHARMA/QAM/QAM_EXECUTION_REPORT.md) · [Preflight evidence](/home/moose/nextjs/CYBER_PHARMA/cyber-pharma-dev-v1-phase-3/agent_docs/ACTIONS/RRM-004-CYBER-PHARMA/QAM/evidence/QAM_PREFLIGHT_Q1.txt) · [Recon evidence](/home/moose/nextjs/CYBER_PHARMA/cyber-pharma-dev-v1-phase-3/agent_docs/ACTIONS/RRM-004-CYBER-PHARMA/QAM/evidence/recon.txt)

HEAD remains `5362b79ca724e454011e77aeaf4b11101176d0b5`. Only QA artifacts and this session’s report/log are dirty; nothing was committed.

```text
 M agent_docs/ACTIONS/RRM-004-CYBER-PHARMA/QAM/QAM_EXECUTION_REPORT.md
 M agent_docs/ACTIONS/RRM-004-CYBER-PHARMA/QAM/QAM_TEST_PLAN.md
?? agent_docs/ACTIONS/RRM-004-CYBER-PHARMA/QAM/AUTOMATION/
?? agent_docs/ACTIONS/RRM-004-CYBER-PHARMA/QAM/evidence/
?? agent_docs/RESPONSES/response_2026-10-01_134927_rrm004-qam-q1-recon.md
?? agent_docs/SESSIONS/session_2026-10-01_rrm004-qam-q1.md
```

Awaiting the QA Lead/Architect’s AC-403 ruling and QA Lead plan approval. [QAM operating law requires this stop](/home/moose/nextjs/CYBER_PHARMA/cyber-pharma-dev-v1-phase-3/agent_docs/ACTIONS/RRM-004-CYBER-PHARMA/QAM/AGENTS.md:42) when an unresolved contract contradiction determines an AC’s grade.
